Back to resultsCortisol in the Treatment of Phobias
Primary Purpose
Phobia
Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Cortisol
Sponsored by
About this trial
This is an interventional treatment trial for Phobia focused on measuring phobia, cortisol, memory, treatment
Eligibility Criteria
Inclusion Criteria:
- Female and male patients with a specific phobia (fear of heights) according to DSM-IV criteria.
Exclusion Criteria:
- Severe acute or chronic somatic diseases
- Psychiatric disorder other than specific phobia
- Topic glucocorticoid therapy (for large skin parts)
- Inhaled glucocorticoids
- Psychotropic medication
- Pregnancy
Sites / Locations
- University of Basel
Outcomes
Primary Outcome Measures
visual analog scales for fear and acrophobia questionnaires
Secondary Outcome Measures
Full Information
NCT ID
NCT00451750
First Posted
March 21, 2007
Last Updated
January 11, 2010
Sponsor
University of Zurich
Collaborators
University Hospital, Basel, Switzerland
1. Study Identification
Unique Protocol Identification Number
NCT00451750
Brief Title
Cortisol in the Treatment of Phobias
Official Title
The Efficacy of Cortisol in Combination With Behavioral Therapy in the Treatment of Phobias
Study Type
Interventional
2. Study Status
Record Verification Date
January 2010
Overall Recruitment Status
Completed
Study Start Date
May 2007 (undefined)
Primary Completion Date
September 2009 (Actual)
Study Completion Date
September 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University of Zurich
Collaborators
University Hospital, Basel, Switzerland
4. Oversight
5. Study Description
Brief Summary
The aim of this prospective, double-blind, placebo-controlled, randomized study is to investigate if glucocorticoid treatment, in combination with exposure therapy, helps to reduce phobic fear in patients with phobia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Phobia
Keywords
phobia, cortisol, memory, treatment
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Cortisol
Intervention Description
20 mg for 3 times
Primary Outcome Measure Information:
Title
visual analog scales for fear and acrophobia questionnaires
Time Frame
1 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
- Female and male patients with a specific phobia (fear of heights) according to DSM-IV criteria.
Exclusion Criteria:
Severe acute or chronic somatic diseases
Psychiatric disorder other than specific phobia
Topic glucocorticoid therapy (for large skin parts)
Inhaled glucocorticoids
Psychotropic medication
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominique JF de Quervain, MD, Prof.
Organizational Affiliation
University of Zurich
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Frank Wilhelm, Prof.
Organizational Affiliation
University of Basel
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Basel
City
Basel
ZIP/Postal Code
4055
Country
Switzerland
12. IPD Sharing Statement
Citations:
PubMed Identifier
16567641
Citation
Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, Roozendaal B, de Quervain DJ. Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5585-90. doi: 10.1073/pnas.0509184103. Epub 2006 Mar 27.
Results Reference
background
Learn more about this trial
Cortisol in the Treatment of Phobias
We'll reach out to this number within 24 hrs